Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Silky Beaty"'
Autor:
Robert R. McLean, Adam P. Sima, Silky Beaty, Eric A. Jones, Thomas Eckmann, Robert Low, Laura McClung, Rebecca L. Spitzer, Jeffrey Stark, April Armstrong
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2753-2768 (2023)
Abstract Introduction Near-complete skin clearance has become a rapidly achievable treatment goal for patients with psoriasis receiving systemic biologic therapies. However, real-world evidence for durability of near-complete skin clearance and risk
Externí odkaz:
https://doaj.org/article/696be3c47b33493188d9b4bdb97f886c
Autor:
Robert R. McLean, Adam P. Sima, Silky Beaty, Robert Low, Rebecca L. Spitzer, Jeffrey L. Stark, Elizabeth Lesser, Edward Lee, April Armstrong
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2739-2751 (2023)
Abstract Introduction Complete and near-complete skin clearance have become achievable treatment goals for patients with psoriasis receiving systemic biologic therapies. However, there is limited real-world evidence regarding the impact of the degree
Externí odkaz:
https://doaj.org/article/f97a71f5efb648caa6cc8cca86a89526
Autor:
Silky Beaty, Ning Rosenthal, Julie Gayle, Prashant Dongre, Kristen Ricchetti-Masterson, Denise H. Rhoney
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
ObjectiveThis study aimed to examine the epidemiology of seizures, clinical outcomes, and antiseizure medication treatment patterns among seizure patients treated in United States hospitals.DesignA retrospective cross-sectional study was conducted us
Externí odkaz:
https://doaj.org/article/38b02ebab241408391e0914ac33ac05b
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Background: Seizures are common among hospitalized patients. Levetiracetam (LEV), a synaptic vesicle protein 2A (SV2A) ligand, is a common intravenous (IV) anti-seizure medication option in hospitals. Brivaracetam (BRV), a selective SV2A ligand for t
Externí odkaz:
https://doaj.org/article/57bc304969554b629ad7452835d9b885
Publikováno v:
Drugs-Real World Outcomes
Background Adherence to antiepileptic drugs (AEDs) remains the primary management tool to prevent recurrent seizures in patients with epilepsy. Adverse events associated with AEDs could have an impact on adherence and result in treatment failures. Ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5af91ee2f2243fd794341a614574ca10
http://europepmc.org/articles/PMC7984129
http://europepmc.org/articles/PMC7984129
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Frontiers in Neurology
Frontiers in Neurology
Background: Seizures are common among hospitalized patients. Levetiracetam (LEV), a synaptic vesicle protein 2A (SV2A) ligand, is a common intravenous (IV) anti-seizure medication option in hospitals. Brivaracetam (BRV), a selective SV2A ligand for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994f021c63f0e80cebcb456860b65891
https://www.frontiersin.org/articles/10.3389/fneur.2021.760855/full
https://www.frontiersin.org/articles/10.3389/fneur.2021.760855/full
Publikováno v:
Journal of managed carespecialty pharmacy. 26(12)
BACKGROUND: The cost of epilepsy is usually reported as total expenditure over a certain period. However, with the increased availability of acute treatments for use in the community setting, intermittent, single-seizure treatment is now possible in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4144e114b89aec01ebb1ecc780bf7d6
https://pubmed.ncbi.nlm.nih.gov/33103619
https://pubmed.ncbi.nlm.nih.gov/33103619